In this SABCS 2007 summary, Dr. Kathy D. Miller discusses results of a number of studies that may influence treatment decisions for women with metastatic breast cancer.
Advances in understanding the biology of myelodysplastic syndromes and the role of new and emerging treatment options are reviewed in this summary from ASH 2007. Medscape Hematology-Oncology
In this Expert Interview from ASCO 2008, Dr. Robert Motzer discusses the evolving role of mTOR inhibition in the treatment of renal cell carcinoma, with a focus on the newest agent in the class. Medscape Hematology-Oncology
Erythropoiesis-stimulating agents should continue to have an oncology indication, even though questions about their safety remain. Medscape Medical News
Compared with arzoxifene, tamoxifen provides longer progression-free survival and time to treatment failure in women with locally advanced and metastatic breast cancer, according to a report in the November 1st Journal of Clinical Oncology. Reuters Health Information